Evaluating Daily Kefir Intake During Pregnancy to Prevent Gestational Diabetes and Support Gut Health A Randomized Controlled Trial
Led by University of New Brunswick · Updated on 2026-09-28
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Pregnancy involves important changes in metabolism and insulin resistance, especially in the second trimester, which can affect the risk of gestational diabetes mellitus GDM. The maternal gut microbiome also shifts during pregnancy and may impact glucose regulation. Researchers are evaluating whether drinking kefir, a fermented milk drink with beneficial bacteria and yeasts, daily from mid-pregnancy can improve blood sugar and insulin control, reduce GDM risk, and influence the gut microbiome among pregnant individuals.
Participants will be randomly assigned to either a kefir group, consuming 250 mL of kefir daily from about 14 weeks gestation until the routine GDM screening at 26-28 weeks, or a control group receiving usual prenatal care without kefir. Both groups will continue their normal diet otherwise. The study includes four in-person visits for data collection at baseline, mid and late pregnancy screening windows, and one month postpartum.
During the study, researchers will collect blood glucose and insulin measurements, dietary information, stool and breastmilk samples, body composition, and other health data. Key outcomes include maternal glucose and insulin regulation, incidence of GDM, gut microbiome diversity and metabolites, maternal body composition, breastmilk makeup, and infant growth measures. The trial aims to provide evidence on whether kefir can serve as a practical nutrition approach to support metabolic health during pregnancy and improve outcomes for mother and baby.
Pregnant at 14 weeks and 3 days or less at enrollment
Able and willing to attend four in-person study visits during pregnancy and postpartum
Willing to comply with study group assignments including daily kefir if assigned
Willing to avoid kefir if in the control group until the 26-28 week visit
Willing to provide biological and clinical samples such as stool and blood glucose/insulin data
No probiotic, prebiotic, synbiotic, or antibiotic use during first trimester or at enrollment
Not currently consuming probiotic, prebiotic, synbiotic, or antibiotic supplements
Willing to avoid probiotic, prebiotic, and synbiotic supplements until after the 26-28 week visit
Does not engage in regular moderate-to-vigorous physical activity
No recent or active infectious illness or significant gastrointestinal symptoms in first trimester
No history of bariatric surgery
Able to communicate in English or French
Living in Fredericton, New Brunswick and not planning to relocate before one-month postpartum visit
You will not qualify if you...
Pre-existing metabolic diseases affecting glucose regulation, including type 1 or type 2 diabetes
Current or first trimester use of medications that alter glucose metabolism, such as metformin or semaglutide
Gastrointestinal or inflammatory diseases including Crohn's disease, ulcerative colitis, celiac disease, or irritable bowel syndrome
Allergy, intolerance, or contraindication to dairy or kefir components
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
4 in-person visits at baseline, 18-20 weeks, 26-28 weeks, and 1 month postpartum
Intervention
Duration - Approximately 12 to 14 weeks
Participants in the kefir group drink 250 mL of kefir daily from about 14 weeks gestation until the routine gestational diabetes screening window at 26-28 weeks. Control group participants continue usual prenatal care without kefir.
Visits at baseline, 18-20 weeks, 26-28 weeks, and 1 month postpartum for assessments
Follow-up
Duration - 1 month postpartum
Researchers collect postpartum data including maternal health, breastmilk samples, and infant growth assessments one month after birth.
1 postpartum visit
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
AGEWISE Study on Gut Microbiome and Hormonal Changes in Women Aged 40 to 64 During Menopause
Quality of Life and Psychological Factors in Women Aged 20 to 40 with Gestational Diabetes Mellitus
Study on How Birth Methods and Pregnancy Conditions Affect Exclusive Breastfeeding for Three Months
Effects of Blackcurrant Supplements on Bone Health and Gut Microbiome in Postmenopausal Women
A Randomized, Placebo-Controlled Trial Using Multi-Omics to Understand Bone Loss Prevention
Study of Cardiometabolic Disease, Insulin Resistance, and Placental Health in Pregnant Women at Risk
Study of Fasting Combined with Dietary Fiber to Improve Gut Microbiome and Metabolic Health
Comparing Metformin and Glyburide for Managing Blood Sugar in Pregnant Women with Gestational Diabetes
Pilot Study on Curcumin Supplementation for Retinal Amyloid Beta in Adults Aged 40 to 89
Study to See How Eating ProteinFat Before Carbs Affects Blood Sugar in Pregnant Women with Gestational Diabetes
Evaluating Daily Kefir Intake During Pregnancy to Prevent Gestational Diabetes and Support Gut Health A Randomized Controlled Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Preventive effect of probiotics supplementation on occurrence of gestational diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
A Comprehensive Review of Gestational Diabetes Mellitus: Impacts on Maternal Health, Fetal Development, Childhood Outcomes, and Long-Term Treatment Strategies.
Risk factors for gestational diabetes mellitus and postpartum glucose intolerance: a retrospective study from a hospital specializing in infertility treatment.